# members are listed at the end of the paper a B S T r a c T BacKGrOUNd: We developed a model to estimate the female age-dependent decrease in blastocyst euploidy and the impact of blastocyst cohort size on the likelihood of having at least one euploid blastocyst for transfer. meTHOdS: retrospective analysis of 1296 trophectoderm biopsies by next-generation sequencing analysis from 436 infertile couples undergoing intracytoplasmic sperm injection and preimplantation genetic testing for aneuploidy. A logistic regression model was fit to the data. The dependent and independent variables were embryo genetic status and female age, respectively. The method of fitting was quadratic on age, and the model was validated with cross validation by a data splitting technique. reSULTS: The decrease in the probability of blastocyst euploidy follows an age-dependent binomial distribution, progressing with every year of female age, from 1.2% to 24.5% in 28-44 years-old women (P<0.0001). The minimum number of blastocysts needed to obtain at least one euploid blastocyst for transfer was computed for different probabilities and female ages. at the age of 28 years, a total of three blastocysts is required to obtain at least one euploid blastocyst with 90% probability, whereas it is 4, 5, 6, 9, 16 and 29 for ages 35, 37, 39, 41, 43, and 45, respectively. cONcLUSiONS: a novel prediction model estimates the probability of blastocyst euploidy and the number of blastocysts required to obtain at least one euploid embryo for transfer. This new resource based on f emale age and blastocyst cohort size will aid clinicians counsel and plan treatment of infertile couples undergoing iVF/icSi.
a neuploidy affects more than one-half of human embryos and is the most likely reason for the decrease in live birth rates among aging women undergoing assisted reproductive technology (arT). [1] [2] [3] The use of advanced molecular cytogenetic techniques for assessment of embryo ploidy status is increasing steadily among couples undergoing arT. analysis of blastocyst trophectoderm biopsy specimens is usually carried out by array comparative eSTeVeS aGe-dePeNdeNT decreaSe iN BLaSTOcYST eUPLOidY 4 PaNmiNerVa medica march 2019
Inclusion and exclusion criteria
PGT-a was used for reasons of advanced maternal age, severe male factor infertility, recurrent miscarriage, repeated implantation failure, as well as for patients who were concerned about the euploidy status of their embryos. Women who underwent preimplantation genetic testing for balanced translocations or single-gene diseases, polar body biopsy, and PGT on day 3 embryos were excluded. embryos generated from oocyte donation cycles were also excluded. additionally, we excluded PGT-a results from frozen-thawed blastocysts.
Trophectoderm biopsy and analysis by next-generation sequencing
The biopsy was applied to the trophectoderm on days 5 or 6 of embryo culture by cutting a small piece of trophectoderm (5-10 cells) with the use of laser (Octax Tm , mTG, Germany). Briefly, biopsies were performed under the inverted microscope on a heated stage. a holding pipette was used to support the blastocyst. The biopsy pipette with an inner diameter of 20-30 micrometers was used to pull and separate the trophectoderm cells from the rest of the blastocyst. a laser was used to drill the zona pellucida to facilitate hatching of trophectoderm cells. Laser pulses were also applied to the constricted area of cells at the end of the biopsy pipette to facilitate cells separation from the blastocyst. The biopsied fragment was then immersed into 0.2 mL Pcr tubes in a total volume of 2.5 uL of Tris-edTa Buffer pH 8.0 (ThermoFisher Scientific Baltics, Vilnius, Lithuania), frozen at -20 celsius degrees, and shipped to the central laboratory for genetic analysis.
Next-generation sequencing analysis
Biopsied trophectoderm cells were subjected to nextgeneration sequencing (NGS) analysis of 24 chromosome copy numbers with the purpose of transferring only diagnosed euploid embryos. Briefly, samples underwent cell lysis, whole genome amplification (WGA), and construction of libraries using the ion reproseq kit (ThermoFisher Scientific, Karlsruhe, Germany). The DNA quantity was estimated using StepOne (ThermoFisher Scientific) following manufacturer's protocol, and NGS was carried out using the ion Torrent PGm™ platform (ThermoFisher Scientific). Euploidy data analysis was performed using ion reporter software version 5.2 calibrated at medium sensitivity, using Low-coverage Whole-Genome workflow. For reporting embryo results, copy numbers were measured quantitatively, and embryos were classified acgenomic hybridization (acGH), quantitative polymerase chain reaction (qPcr), single-nucleotide polymorphism (SNP array), and more recently, by next-generation sequencing (NGS). 4, 5 These methods have widely replaced fluorescence in situ hybridization (FiSH) analysis as they provide accurate information on the copy numbers of all 24 chromosomes. array cGH data indicate that female age is the most significant determinant of embryo genetic status and that aneuploidy rates do not differ significantly by embryo cohort size in women of same age. 1 although acGH is a robust method to assess embryo ploidy, recent reports suggest that NGS might have higher sensitivity than acGH. 6, 7 However, data concerning the effect of female age on blastocyst euploidy using NGS is lacking.
in this study, we developed an age-dependent model to estimate the probability of blastocyst euploidy and determined the magnitude of the decrease in this probability with each year of female age. The model allowed us to derive a mathematical function to estimate the number of blastocysts needed to obtain at least one euploid blastocyst for transfer in each patient undergoing arT. This estimation is aligned with the recently published new marker of successful outcome in arT by the POSeidON group, namely, the ability to retrieve the number of oocytes required to obtain at least one euploid embryo for transfer in each patient. 8, 9 Our goal is to provide clinicians working in the field of reproductive medicine: 1) individualized estimates of the couple's probability of having a euploid blastocyst, based solely on female age; 2) a pretreatment clinical tool to calculate the age-adjusted number of blastocysts needed to achieve at least one euploid blastocyst for transfer.
Materials and methods
This study is a retrospective analysis of preimplantation genetic testing results from fresh human blastocysts tested for aneuploidy by NGS (PGT-a). We included 1296 consecutive trophectoderm biopsies from 436 infertile couples undergoing intracytoplasmic sperm injection (icSi) cycles and PGT-a assessed by chromosome Genomic center between 2016 and 2017. The database used for this study was anonymized and only included data concerning female age, the number of blastocysts biopsied, and the ploidy status of biopsied blastocysts. The study was approved by the ethics committee of instituto investiga, campinas, Brazil. and only euploid or aneuploid blastocysts were included. The dependent and independent variables were the embryo genetic status (euploid/aneuploid) and female age, respectively. We made the following simplifying hypotheses: 1) the embryos are statistically independent concerning the ploidy status; 2) the probability of an embryo being euploid is constant across women and cycles, depending solely on female age. With these two hypotheses, the random variable "number of euploid blastocysts given N blastocysts" is distributed as a binomial random variable, with parameters N and p, where p -the probability of an embryo to be euploid -is a function of the patient's age. The best model was chosen and validated by randomly splitting two portions of the data, 80% for training and the remaining 20% for testing. computations were carried out using JmP ® PrO 13 (www.jmp.com). a mathematical formula was developed to estimate the number of blastocysts required for obtaining at least one euploid blastocyst.
Results
The dataset included 1299 blastocyst biopsies (96.5%) which yielded NGS data whereas 46 blastocysts (3.5%) provided cells with degraded dNa caused by nucleated biopsied cells or low embryonic quality. Three mosaic embryos were excluded from the analysis. The mean±Sd female age was 37.4±3.5 years (range: 32-45 years-old). The overall euploid blastocyst rate was 36.5% (473/1296).
Frequencies of euploid blastocysts across female age and embryo cohort size
The percentages of euploid embryos stratified by age and embryo cohort size are presented in Table i . The mean cording to the PGdiS criteria, as follows: embryos with >80% abnormal cells were classified as aneuploid, whereas embryos with <20% abnormal cells were deemed normal (euploid). in contrast, embryos between 20% and 80% abnormal cells were classified as mosaic embryos. 10 
Outcome measures
The following outcome measures were assessed: 1) mean frequencies of euploid blastocysts across arbitrarily predefined age bins, namely, 28-33 years, 34-35 years, 36-37, 38-39, 40-41, 42-43, and 44-45 years; 2) proportion of women with at least one and two euploid blastocyst by age bins according to arbitrarily predefined blastocyst cohort size categories, namely, 1-4, 5-7, and 8-10; 3) estimation of blastocyst euploidy probability as a function of female age; 4) estimation of the age-dependent decrease in blastocyst euploidy probability, and 5) estimation of the number of blastocysts required for achieving at least one euploid embryo as a function of female age, for the fixed probabilities of 80% and 90%.
Statistical analysis
The proportion of euploid blastocysts was computed as a function of blastocyst cohort size and female age. The percentage of women with at least one and two euploid blastocysts was also determined across all studied categories. The blastocyst euploidy rates were compared using the χ 2 test.
Furthermore, logistic regression analyses were carried out to determine the probability of blastocyst euploidy by age and the correspondent percentage decrease in these probabilities by each additional year of female age. For these analyses, the outcomes refer to biopsied blastocysts, (t) in years. There was no statistical evidence against the fitted model (p>0.10).
To determine the predictive ability of the model, we used a validation strategy based on two randomly chosen portions of the data, one for training (80% of the data points) and the remaining 20% for testing (Supplementary digital material 2, Supplementary Table ii). The generalized rsquare was 11% on the training and reached 19% on the test dataset. A model-independent verification by aggregating the data in age brackets (data binning) confirmed that the model is not biased as there is linearity in the relationship between the estimated probability distribution and the distribution of empirical data, as seen in the quantile-quantile plot (Supplementary digital material 3, Supplementary Table III) (Figure 1 ). The fitted probabilities with 95% confidence intervals are shown in Figure 3 . blastocyst euploid rate was significantly different among the groups of women (χ 2 =523.60645; P<0.001). The frequency of women with at least one and two euploid blastocysts across female age bins, stratified by embryo cohort size, is shown in Figure 1 , 2. The mean frequency of patients with at least 1 or 2 euploid blastocysts was lower in the small cohort size (1-4 blastocysts) across all age groups than in the larger cohorts (>4) (P<0.001). No difference was observed in the frequencies of euploid blastocyst across embryo cohort categories within the same female age (Table i) .
Model development to estimate the age-dependent decrease in blastocyst euploidy and the number of blastocysts needed for obtaining at least one euploid blastocyst
The quadratic model on age was significant (Prob>χ 2 = 0.028; Supplementary digital material 1, Supplementary Table i ). The derived model was log[p(t)/ (1−p(t))]=7.575-0.21•age-0.011•(age-38.41), 2 where p(t) is the probability of a blastocyst being euploid for age 
Estimation of the age-dependent decrease in blastocyst euploidy
The percentage decrease in blastocyst euploidy probability from year (t) to year (t+1) was defined as the ratio p(t+1)/ p(t) x 100. There was a significant (P<0.0001) decrease in the probability of a blastocyst being euploid with every year of female age. The geometric mean of the yearly variation was 13.6%. The decrease is progressive with every year of female age (Figure 4) . at age 29 it was 1.2%, whereas at ages 30, 32, 35, 37, 39, 41 and 44, the decreases were 2.0%, 3.5%, 6.7%, 9.8%, 13.6%, 17.9%, and 24.5%, respectively.
Female age and blastocyst cohort size-based prediction model to estimate the probability of obtaining at least one euploid blastocyst
Given premises on the independence of outcomes and constancy of the probabilities, the number of euploid blastocysts is a binomial random variable. Based on this and the estimates of the probabilities given by the model, a formula was developed to calculate the number of blastocysts required to achieve at least one euploid blastocyst. The minimum number of blastocysts needed for obtaining at least one euploid blastocyst for transfer can be computed for different probabilities of the final outcome, i.e., at least one euploid blastocyst, as shown in Supplementary digital material 4 (Supplementary Figure 1, Supplementary Text  File) . at the age of 28 years, the model estimates that a total of three blastocysts is required to obtain at least one euploid blastocyst with 90% probability, whereas it is 4, 5, 6, 9, 16 and 29 for ages 35, 37, 39, 41, 43, and 45, respectively ( Figure 5 ). Furthermore, an embryo cohort size of 2, 3, 5, 7, and 11 are required to obtain at least one euploid blastocyst with 80% probability for ages 28, 35, 39, 41, and 43, respectively (Table ii) .
Discussion
To our knowledge, our study is the first to estimate the age-related probability of blastocyst euploidy using NGS data from fresh trophectoderm human cells. We showed that the decrease in the probability of blastocyst euploidy is not only age-dependent but also progressive with every year of female age. Based on logistic regression analyses, we developed a novel pretreatment clinical predictive model based on female age to estimate the minimum blastocyst cohort size needed to achieve at least one euploid fate of patients undergoing arT, as approximately 60% of euploid blastocysts implant across all age categories. 3 Thus, estimating such numbers might guide clinicians to plan treatment with the mindset to achieve this goal. Our study depended primarily on female age and NGS analysis of blastocyst biopsies. We used female age as the independent variable due to the results of previous reports confirming its strong association with ART outcomes. 1, [13] [14] [15] in particular, the age of the woman seems to be the most critical covariate for determining the likelihoods of embryo euploidy rates and live birth. 1, 14, 15 The progressive reduction in the primordial follicle number across the female lifespan as well as the increase in oocyte chromosomal abnormalities and cytoplasmic dysfunctions cause the decline in fertility with aging. 16 These phenomena ultimately result in a reduction of embryo quantity and quality, thus explaining to a great extent why iVF success is lower in women of advanced age than in young counterparts. in a 2012 study, ata et al. retrospectively evaluated 990 patients who underwent iVF/icSi with PGT-a by aCGH. The authors showed a significant decrease in the euploidy rate of both cleavage-state embryos and blastocysts with increasing female age. 1 Similarly, in 2018, La marca et al. assessed the ploidy status of 1814 embryos from 578 patients undergoing arT and PGT-a by acGH and showed a robust female-age effect on the rates of euploid blastocysts. 15 The authors also suggested that other covariates, such as the levels of anti-müllerian hormone, might also affect blastocyst euploidy rates.
While both studies mentioned above utilized acGH as the method for analysis and embryo selection, our results were based exclusively on NGS of biopsied blastocysts. The reason for this is the fact that NGS is the current method used by The chromosome Genomic center -a unit dedicated to providing genetic services to fertility clinics in Brazil -owing to the growing body of evidence indicating NGS to be superior to acGH for embryo aneuploidy assessment. [4] [5] [6] [7] Here, we add to the literature by providing NGS data concerning the ploidy status of human embryos as a function of female age.
Until now, the influence of female age on embryo ploidy status has been measured by the arithmetic average, 1, 15 which represents the mean number of euploid/ aneuploid embryos in a given patient age category. The problem for the communication of critical statistical facts using arithmetic average is that this measure is a property of a group and not an individual. Thus, assuming that the properties of a group can be used to make predictions about members of that group might lead to error and conblastocyst for transfer. Our NGS data also indicated that the proportion of women with at least one and two euploid blastocysts decreases with age. moreover, our NGS data corroborate a previous acGH report 1 indicating that the blastocyst cohort size has a significant impact on the likelihood of having at least one euploid blastocyst for transfer following in-vitro fertilization (iVF) and icSi. This observation is due to the fact that the number of euploid blastocysts will, in a probabilistic sense, depend on the number of "opportunities," i.e., the blastocyst cohort size. Lastly, we showed that the blastocyst cohort size has no significant impact on the mean rates of blastocyst euploidy among patients of the same age.
We quantified the probability of a cohort to include at least one euploid blastocyst. Our results are important for reproductive medicine specialists and patients who will undergo arT, and mostly so for women of advanced reproductive age. Using our model, counseling and treatment planning can be done in terms of the couple's probability of having a euploid blastocyst and the number of blastocysts needed to achieve this goal. For instance, our model indicates that a patient of 39 years will require between 5 to 6 blastocysts to have at least one euploid blastocyst available for transfer, with an 80% and a 90% probability, respectively. For most aging patients, this number of blastocysts might not be feasible in a single stimulation cycle owing to the reduced ovarian reserve. Provision of such objective information to our patients enhances transparency, set expectations, and might help them prepare both emotionally and financially for the infertility treatment journey. From a clinical perspective, an individualized approach will demand consideration of all steps of arT to secure the shortest time to live birth, including the choice of GnrH analogue, gonadotropin type and dose, ovulation trigger, and the possible use of adjuvant therapies as well as double stimulation in the follicular and luteal phase of the same cycle (duostim). 11, 12 although an estimation of the number of blastocysts needed to achieve a live birth rather than one euploid embryo would be preferable, it might not be practical due to the multitude of controlled and uncontrolled factors influencing LBr. Hence, we used embryo euploidy as a proxy of live birth because it has been suggested to be a more pragmatic intermediate marker of successful outcome. 8, 9 recently, the POSeidON group proposed "the ability to retrieve the number of oocytes needed to obtain at least one euploid blastocyst for transfer in each patient" as the measure of arT success. 9 indeed, the availability of at least one euploid embryo for transfer might change the 
Conclusions
The decrease in the probability of a blastocyst being euploid increases progressively with every year of female age, from 1.2% to 24.5% in 28-44 years-old women. Our novel predictive model based on female age and NGS data estimates the minimum blastocyst cohort size needed to achieve at least one euploid blastocyst for transfer given a specified probability. This information can aid clinicians counsel patients concerning their chances of success when undergoing arT treatment. also, our model can be used to support a risk-based decision analysis about arT treatment options.
fusion. 17 Here, we calculated the probability distribution in addition to reporting the average of blastocyst euploidy for an age group. Probability is a mathematical property that describes the likelihood of an event. in other words, a probability is an assigned property derived from a model, which can be validated to give accurate predictions about a biological phenomenon, like blastocyst euploidy, with its uncertainties. consequently, computing the probability of blastocyst euploid as a function of female age is clinically advantageous as it not only provides the best estimate of the likelihood of the phenomenon of interest but also allows a mathematical calculation of the minimum number of blastocysts needed to achieve at least one euploid blastocyst for transfer, with a quantified uncertainty. By estimating the probability of embryo euploidy on age, we added to the literature by first of all reporting that the decrease in the probability of blastocyst euploidy with increasing age follows a binomial distribution (Figure 3 ). Second, we showed for the first time that the magnitude of the decrease in the probability of blastocyst euploidy progresses with every year of female age. Lastly, we aggregated patients by age after analyzing our dataset using logistic regression, thus allowing development of -to the best of our knowledge-the first pretreatment clinical model to estimate the number of blastocysts needed to achieve at least one euploid blastocyst for transfer based on female age.
Limitations of the study
The impact of other covariates that could impact embryo genetic status and the effect of cycle number were not analyzed. an ongoing study by the POSeidON consortium will analyze the effect of other covariates than female age on embryo ploidy status. Furthermore, our estimations cannot be generalized to iVF patients undergoing cleavage-stage embryo transfer as our study is based on blastocyst biopsies and NGS analysis. along these lines, we did not assess the accuracy of our estimations using other genetic analysis platforms. Lastly, our model should be used with caution to decide whether or not a patient should undergo fertility treatment.
Future research
The impact of other covariates on blastocyst euploidy should be investigated. also, estimation of the number of oocytes needed to obtain at least one euploid blastocyst might be advantageous for both counseling purposes and therapeutic planning. currently, a model taking the above
